New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.
Best Practices for Most Vulnerable Populations: Transgender People, Adolescents, and the Recently Incarcerated
"As we think about the care cascade, we can't even test people [for HIV] to diagnose them if we can't get them in the door to a health care setting," one clinician said.
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.
Steven Deeks, M.D., talks about the medical community's hopes, inspirations, and unanswered questions regarding research for an HIV cure.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
Having Fallen Out of Care, Most Gay and Bisexual Men With Detectable HIV Viral Loads Were Successfully Reconnected, Study Finds
The study enrolled more than a thousand people in four U.S. cities: Atlanta, Baltimore, Birmingham, and Boston.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
More research is needed to understand the connections between HIV, mental health, and the neurocircuitry that controls executive function.